structurebas
design
synthesi
biolog
evalu
seri
peptidomimet
sever
acut
respiratori
syndromecoronaviru
chymotrypsinlik
proteas
inhibitor
describ
inhibitor
design
synthes
base
upon
xray
crystal
structur
inhibitor
bound
sarscov
incorpor
bocser
p
ligand
result
enhanc
sarscov
inhibitori
activ
structur
analysi
inhibitorbound
xray
structur
reveal
high
bind
affin
toward
enzym
structurebas
design
synthesi
biolog
evalu
peptidomimet
sarscov
inhibitor
sever
acut
respiratori
syndrom
sar
contagi
fatal
respiratori
ill
first
report
guangdong
provinc
china
novemb
rapid
unexpect
spread
asian
countri
north
america
europ
alarm
public
world
health
organ
sar
caus
novel
coronaviru
sarscov
emerg
affect
individu
caus
death
within
month
signifi
rapidli
contagi
ill
spread
mobil
highli
interconnect
world
centuri
remark
world
wit
concert
intern
cooper
allow
health
expert
identifi
novel
etiolog
agent
contain
sar
epidem
month
emerg
current
known
sar
transmiss
anywher
world
time
guarante
outbreak
strike
even
sever
form
thu
far
effect
therapi
exist
viral
infect
sarscov
positivestrand
rna
viru
whose
genom
sequenc
reveal
moder
relat
known
coronavirus
viral
replic
viral
replicas
polyprotein
undergo
extens
process
two
viral
proteas
name
chymotrypsinlik
proteas
papainlik
proteas
plpro
gener
function
viral
replic
complex
therefor
sarscov
sarscov
plpro
recogn
logic
target
therapeut
intervent
sarscov
relat
interact
structur
activ
sarscov
investig
enzym
activ
site
contain
catalyt
dyad
cystein
residu
act
nucleophil
histidin
residu
act
gener
acid
base
sarscov
function
analog
main
picornavir
proteas
signific
drugdesign
effort
human
rhinovir
proteas
also
cystein
proteas
recent
describ
structurebas
design
number
potent
sarscov
inhibitor
inhibitor
design
base
upon
modif
potent
inhibitor
human
rhinovir
proteas
exhibit
inhibitori
activ
sarscov
modifi
inhibitor
activ
enzymat
assay
well
cell
cultur
assay
xray
structur
inhibitorbound
reveal
import
molecular
insight
ligandbind
site
enzym
inhibitor
bind
sarscov
coval
bond
activ
site
cystein
residu
base
upon
molecular
insight
modifi
initi
inhibitor
accommod
specif
ligandbind
site
interact
subsit
sarscov
activ
site
herein
describ
synthesi
biolog
evalu
xray
structur
inhibitorbound
sarscov
two
potent
peptid
peptidomimet
inhibitor
fig
describ
previous
inhibitor
make
number
import
interact
enzym
activ
site
includ
coval
bond
form
thiol
bunsatur
ester
subsit
make
hydrogen
bond
p
lactamnh
nitrogen
make
hydrogen
bond
keton
inhibitor
p
oxazol
group
appear
fill
hydrophob
pocket
base
upon
xray
structur
subsequ
specul
replac
p
oxazol
bocserin
p
ligand
would
promot
addit
hydrogenbond
interact
site
result
enhanc
inhibitori
potenc
also
evalu
correspond
peptidederiv
inhibitor
studi
synthesi
inhibitor
outlin
scheme
synthet
procedur
silyl
ether
deriv
describ
us
previous
remov
silyl
protect
group
tetrabutylammonium
fluorid
thf
provid
secondari
alcohol
oxid
keton
dessmartin
periodinan
yield
step
keton
convert
inhibitor
exposur
trifluoroacet
acid
tfach
cl
follow
coupl
result
amin
boc
l
serin
provid
yield
synthes
peptidebas
inhibitor
summar
scheme
gener
peptid
coupl
reaction
valin
leucin
phenylalanin
follow
ester
hydrolysi
gave
carboxyl
acid
intermedi
yield
respect
coupl
acid
lactam
fragment
afford
bocderiv
yield
respect
exposur
compound
tfa
effect
remov
bocgroup
provid
correspond
free
amin
coupl
amin
boc
l
serin
furnish
inhibitor
yield
respect
furthermor
reaction
amin
acid
afford
inhibitor
good
yield
inhibitori
activ
synthet
inhibitor
shown
tabl
enzym
inhibitori
activ
compound
sarscov
determin
fretbas
micropl
assay
describ
grumtokar
et
al
protocol
previous
use
determin
ic
valu
bunsatur
ester
assay
perform
micropl
use
reaction
volum
contain
mm
hepe
ph
nm
sarscov
enzym
vari
concentr
synthet
inhibitor
reaction
compon
except
substrat
incub
min
reaction
initi
addit
fretsubstr
alexafluor
gluseralathrleuglnserglyleuala
lysqsi
ser
give
final
substrat
concentr
lm
ic
valu
inhibitor
determin
measur
rate
reaction
increas
inhibitor
concentr
shown
tabl
structurebas
incorpor
p
bocser
place
p
oxazol
inhibitor
result
inhibitor
signific
enhanc
enzymat
inhibitori
potenc
antivir
activ
improv
exhibit
antivir
activ
similar
inhibitor
differ
activ
may
due
presenc
peptidelik
featur
inhibitor
peptidelik
molecul
often
exhibit
poor
passiv
transcellular
diffus
across
cell
membran
antivir
assay
follow
previous
publish
protocol
compar
bind
affin
correspond
peptidebas
inhibitor
incorpor
p
oxazol
p
boc
ser
peptidebas
inhibitor
p
leu
p
phe
display
enzymat
potenc
enhanc
respect
inhibitor
contain
p
oxazol
obtain
molecular
insight
bind
properti
inhibitor
determin
xray
structur
sarscov
resolut
refin
statist
data
collect
summar
tabl
stereoview
inhibitorbound
structur
shown
figur
xray
structur
reveal
inhibitor
coval
bond
enzym
via
cs
bond
activ
site
cystein
p
ethyl
ester
carbonyl
within
proxim
oxygen
side
chain
make
hydrophob
contact
p
ligand
furthermor
p
lactam
nh
form
hydrogen
bond
imidazol
ring
p
carbonyl
group
form
hydrogen
bond
nh
p
ser
side
chain
within
hydrogenbond
distanc
glu
may
explain
enhanc
bind
affin
oxazolebear
inhibitor
conclus
structurebas
design
strategi
result
signific
improv
enzym
inhibitori
activ
sarscov
xray
structur
enzym
provid
critic
molecular
insight
ligandbind
site
interact
activ
site
appear
p
bocser
involv
import
hydrogenbond
interact
subsit
present
molecular
insight
facilit
design
effect
inhibitor
investig
progress
tabl
summari
xray
data
process
refin
statist
last
shell
resolut
statist
shown
within
parenthes
b
r
merg
p
ji
hiij
p
observ
intens
hii
averag
intens
multipl
symmetryrel
observ
reflect
measur
reflect
uniqu
reflect
c
r
cryst
p
jjf
ob
j
jf
calc
jj
p
jf
ob
j
jf
ob
j
jf
calc
j
observ
calcul
respect
structur
factor
amplitud
reflect
r
free
r
cryst
except
calcul
set
reflect
use
structur
refin
stage
observ
data
case
figur
xray
crystal
structur
thick
stick
gray
carbon
sarscov
hydrogen
bond
inhibitor
shown
white
dot
line
